Supplemental Figure 1. Urinary glycolate and oxalate in cynomolgus monkeys following multiple doses of ALN-GO1. (A) Urinary glycolate and (B) urinary oxalate levels. Points represent the mean of 3 animals and error bars depict the standard deviation. Arrows indicate dosing days.
Supplemental Figure 2. Urinary Oxalate Levels in Male and Female Sprague Dawley Rats Following a Single dose of HAO1 siRNA. Levels of urinary oxalate pre-dose (Day -1, Day 0) and post-dose (Day 3, Day 7, Day 14) after a single dose of HAO1 siRNA. Points represent the mean of 2 or 3 animals and error bars depict standard deviation.
Supplemental Figure 3. Urinary oxalate changes in an Induced rat model of hyperoxaluria following multiple doses of ALN-GO1. Levels of (A) liver AGXT mRNA on Day 28 (7 days post-last dose) following one i.v. dose per week for 4 weeks of alanine-glyoxylate aminotransferase (AGXT) siRNA formulated in an LNP lipid nanoparticle. Levels of (B) liver HAO1 mRNA on Day 28 (7 days post-last dose) following one subcutaneous dose per week for 4 weeks with ALN-GO1 (C) 24-hour urinary oxalate. Bars represent the mean of 2 or 3 animals and error bars depict the standard deviation. Points represent the mean of 2 or 3 animals and error bars depict the standard deviation.